Latest News

Amy Pearlman, MD, and guests discuss how to address unmet needs in bladder care through telehealth, education, and behavioral interventions.

Kristen Scarpato, MD, discusses 2026 AUA/SUO Advanced Prostate Cancer Guideline amendment recommendations on the use of PSMA-PET imaging for staging and treatment selection.

Data from the ARC-20 study are the first to link HIF-2a inhibitor-associated changes in circulating serum EPO, tumor biology, and clinical activity.

Results from a cross-sectional study suggest that unmet social needs are associated with kidney stone disease and worse stone-specific quality of life.

Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without pre-biopsy mpMRI.

"This is really going to make access to care a lot better, and workflow is going to be a lot easier," says Ben H. Chew, MD, MSc, FRCSC.

In this episode of The UroOnc Minute, host Adam Weiner, MD, is joined by David Canes, MD, for a thoughtful discussion on practical strategies to improve efficiency, reduce physician burnout, and preserve meaningful patient-centered care in urologic oncology.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

Enucleation is appropriate for the vast majority of patients with BPH, but certain patient profiles—including prior radiation, significant neurologic conditions, morbid obesity, and dementia—warrant caution or referral to specialists, whereas the most consistent technical failure among surgeons past their learning curve is inadequate apical tissue removal driven by discomfort with sphincter proximity, according to Amy E. Krambeck, MD.

A recap of the FDA submissions and regulatory decisions in urology from June 2026.

A health-economic analysis of the ASPIRE trial data found that the steerable ureteroscopic renal evacuation (SURE) procedure was linked to roughly $3464 in downstream savings per patient over 2 years compared with standard ureteroscopy, with lead investigator Brett Johnson, MD, framing this as a value-committee benchmark rather than a full cost comparison, since the analysis deliberately excludes the index procedure's incremental cost due to wide variability across payers and care settings.

In this episode, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Nicholas Deebel, MD, to discuss a new men's health program and a clinical trial evaluating incobotulinumtoxinA for erectile dysfunction.

A roundup of the key stories on benign urologic conditions from the second quarter of 2026.